Tag: trastuzumab biosimilars market share

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Trastuzumab Biosimilars Market Set To Climb From $8.86 Billion In 2026 To $24.48 Billion By 2030

The trastuzumab biosimilars market size has experienced substantial expansion in recent years. This market is forecast to increase from $6.9 billion in 2025 to $8.86 billion in 2026, achieving a compound annual growth rate (CAGR) of 28.5%. The historical growth of this market can be linked to the prevalent incidence of HER2 positive breast cancer, the expiration of trastuzumab patent exclusivity, escalating oncology drug costs, established regulatory pathways for biosimilars, and the adoption within hospital oncology settings.

The trastuzumab biosimilars market size is projected to experience substantial growth in the coming years. It is anticipated to reach $24.48 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 28.9%. This expansion during the forecast period can be attributed to factors such as the increasing prevalence of cancer, the broadening of indications to include gastric cancer, favorable reimbursement policies for biosimilars, growing confidence among physicians, and intensified efforts to contain healthcare costs. Key trends expected within this period encompass the rapid uptake of oncology biosimilars, enhanced access to HER2 targeted therapies, increased price competition in breast cancer treatment, wider integration of oncology services within hospitals, and a rising acceptance of biosimilar switching.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=78146983&type=smp&name=Trastuzumab%20Biosimilars%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Trastuzumab Biosimilars Market Demand Drivers Opening New Revenue Streams

The increasing occurrence of breast and gastric cancer has been a key factor in the expansion of the trastuzumab biosimilars market. Trastuzumab biosimilar products are utilized for managing human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For example, in September 2023, the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, estimated that approximately 297,790 new cases of invasive breast cancer would be diagnosed in women in 2023, with about 43,700 women expected to die from breast cancer that same year. Moreover, Cancer India states that breast cancer is the most common cancer among women in India, accounting for 14% of all female cancers. This upward trend in breast and gastric cancer prevalence consequently escalates the demand for trastuzumab biosimilar, which provide a more affordable treatment option compared to costly alternatives, thereby fueling the growth of the trastuzumab biosimilars market.

Trastuzumab Biosimilars Market Segment Analysis And Revenue Potential

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Trastuzumab Biosimilars Market Trends Powering Strategic Industry Growth

Major industry players are continuously prioritizing the launch of new products in untapped regions, a strategy that is actively shaping the market for trastuzumab biosimilars. Companies operating within the trastuzumab biosimilars market are undertaking various strategic initiatives, such as developing new products, forming partnerships, and expanding their geographical footprint and product portfolios, to maintain their competitive standing and better cater to customer requirements. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer. HERCESSI is prescribed for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. While generally aggressive, HER2-positive cancers typically respond effectively to targeted therapies. HERCESSI functions by binding to the HER2 receptor, thereby inhibiting its activity and slowing down the replication of cancer cells.

Trastuzumab Biosimilars Market Key Players Shaping Industry Direction

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

View The Full Trastuzumab Biosimilars Market Report:

https://thebusinessresearchcompany.com/report/Trastuzumab-Biosimilar-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Trastuzumab Biosimilars Market Leading Geography: Which Region Contributes The Most Revenue?

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Trastuzumab Biosimilars Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The market for trastuzumab biosimilars has seen explosive expansion in recent years. Projected to climb from $6.9 billion in 2025 to $8.86 billion in 2026, it is set to achieve a compound annual growth rate (CAGR) of 28.5%. Historical growth during this timeframe was driven by the elevated prevalence of HER2-positive breast cancer, the expiration of trastuzumab’s patent protection, increasing expenses associated with oncology medications, the establishment of regulatory frameworks for biosimilars, and their growing acceptance within hospital oncology departments.

The trastuzumab biosimilars market is projected to experience significant expansion over the coming years, reaching a valuation of $24.48 billion by 2030 with a compound annual growth rate (CAGR) of 28.9%. This anticipated growth during the forecast period is driven by factors such as a rising incidence of cancer, the widening application to gastric cancer indications, supportive reimbursement policies for biosimilars, increased confidence among physicians, and ongoing efforts to curb healthcare expenses. Key developments shaping this forecast period include the swift adoption of oncology biosimilars, enhanced accessibility to HER2-targeted therapies, intensified price competition within breast cancer treatment, an expanded role for hospital-based oncology treatments, and growing endorsement of biosimilar interchangeability.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Trastuzumab Biosimilars Market Growth Factors: Which Forces Are Supporting Market Expansion?

The market for trastuzumab biosimilars has experienced growth due to the increasing incidence of breast and gastric cancer. This type of biosimilar is employed to treat HER2-overexpressing breast cancer and metastatic gastric cancer. As an example, data from September 2023 published by the American Cancer Society, a U.S. nonprofit organization focused on cancer eradication, indicated that roughly 297,790 new invasive breast cancer cases were expected among women in 2023, with around 43,700 fatalities from the disease that same year. In India, Cancer India reports that breast cancer is the most prevalent cancer among women, representing 14% of all female cancer cases. Consequently, the growing prevalence of these cancers has boosted demand for trastuzumab biosimilars, which provide a more affordable alternative to expensive medications, thus propelling the trastuzumab biosimilars market forward.

Trastuzumab Biosimilars Market Categorization By Product Type And Application

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Trastuzumab Biosimilars Market Industry Trends: What Changes Are Reshaping Demand?

Major industry players continue to drive the trastuzumab biosimilars market by introducing new offerings in previously untapped regions. These companies are pursuing a range of strategic actions—such as developing innovative products, forming alliances, and broadening their geographic presence and product lines—to preserve a competitive edge and more effectively address customer demands. A notable example occurred in April 2024, when Accord BioPharma Inc., a pharmaceutical firm based in the United States, received approval from the U.S. Food and Drug Administration (FDA) for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab) used to treat multiple types of HER2-overexpressing cancers. This medication is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. Although HER2-positive cancers tend to be aggressive, they often respond well to targeted therapies. HERCESSI functions by attaching to the HER2 receptor, curbing its activity and consequently decelerating the division of cancer cells.

Trastuzumab Biosimilars Market Company Landscape And Strategic Competition

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

Access The Complete Trastuzumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Trastuzumab Biosimilars Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Trastuzumab Biosimilars Market Between 2026 And 2030?

The size of the trastuzumab biosimilars market has experienced substantial expansion in recent years. It is anticipated to increase from $6.9 billion in 2025 to $8.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 28.5%. This growth observed in the past can be attributed to factors such as the high incidence of HER2 positive breast cancer, the expiration of trastuzumab’s patent, rising oncology drug costs, the establishment of regulatory biosimilar pathways, and greater adoption within hospital oncology settings.

The trastuzumab biosimilars market is anticipated to experience substantial expansion over the coming years, with its size projected to reach $24.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 28.9%. This projected growth during the forecast period is primarily driven by factors such as the rising incidence of cancer, the broadening of indications to include gastric cancer, supportive reimbursement policies for biosimilars, increasing trust among physicians, and initiatives aimed at controlling healthcare costs. Key trends expected during the same period encompass the swift adoption of oncology biosimilars, enhanced availability of HER2-targeted treatments, competitive pricing strategies in breast cancer therapy, an increase in oncology usage within hospitals, and a growing willingness to switch to biosimilar alternatives.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

What Market Drivers Are Helping Shape The Trastuzumab Biosimilars Market Expansion?

The increased incidence of breast and gastric cancer has significantly contributed to the expansion of the trastuzumab biosimilars market. Trastuzumab biosimilars are utilized in the management of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For example, in September 2023, the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, projected around 297,790 new cases of invasive breast cancer to be diagnosed in women in 2023, with approximately 43,700 women expected to succumb to breast cancer in the same year. Moreover, Cancer India states that breast cancer is the most common cancer among women in India, constituting 14% of all cancers in women. This escalating prevalence of breast and gastric cancer consequently drives the demand for trastuzumab biosimilars, which provide a more economical alternative to expensive medicines, thereby propelling the trastuzumab biosimilars market.

What Are The Core Segment Classifications In The Trastuzumab Biosimilars Market?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Which Trends Are Contributing To Changes In The Trastuzumab Biosimilars Market?

Leading industry participants are consistently prioritizing the introduction of novel products into previously unaddressed territories, which is significantly influencing the market for trastuzumab biosimilars. Organizations active within the trastuzumab biosimilars market are implementing diverse strategic initiatives, including the creation of new products, fostering collaborations, and expanding their geographical reach and product portfolios, all aimed at sustaining their competitive edge and more effectively addressing customer demands. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, revealed that the U.S. Food and Drug Administration (FDA) had granted approval for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), intended for the Treatment of Several Forms of HER2-Overexpressing Cancer. HERCESSI is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. While HER2-positive cancers are typically aggressive, they demonstrate effective responses to targeted therapies. HERCESSI operates by binding to the HER2 receptor, thereby inhibiting its activity and consequently slowing down the replication of cancer cells.

Which Companies Form The Competitive Landscape Of The Trastuzumab Biosimilars Market?

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

Access The Complete Trastuzumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Region Has The Strongest Presence In The Trastuzumab Biosimilars Market?

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Trastuzumab Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

Browse Through More Reports Similar to the Global Trastuzumab Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Trastuzumab Biosimilars Market Be By 2030 Compared To Its 2026 Market Size?

The trastuzumab biosimilars market size has experienced substantial expansion in recent years. Its value is anticipated to rise from $6.9 billion in 2025 to $8.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 28.5%. The historical increase in this market can be attributed to factors like the elevated prevalence of HER2 positive breast cancer, the expiry of trastuzumab’s patent exclusivity, escalating costs of oncology medications, established regulatory avenues for biosimilars, and the integration of oncology care within hospitals.

The trastuzumab biosimilars market size is projected to experience rapid expansion over the upcoming years. By 2030, it is anticipated to reach $24.48 billion, demonstrating a compound annual growth rate (CAGR) of 28.9%. This anticipated growth during the forecast period stems from factors such as the increasing incidence of cancer, the broadening of indications to include gastric cancer, supportive reimbursement policies for biosimilars, enhanced trust among physicians, and intensified initiatives to control healthcare expenditures. Key trends observed within the forecast timeframe encompass the swift adoption of oncology biosimilars, enhanced availability of HER2-targeted treatments, competitive pricing within breast cancer therapy, broader application of oncology treatments in hospitals, and increasing willingness to switch to biosimilar alternatives.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

What Major Factors Are Driving The Trastuzumab Biosimilars Market Forward?

The expansion of the trastuzumab biosimilars market has been fueled by an increase in the occurrence of breast and gastric cancer. Trastuzumab biosimilar is utilized in the management of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For instance, in September 2023, the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, indicated that approximately 297,790 new cases of invasive breast cancer are anticipated to be diagnosed in women in 2023, and about 43,700 women are expected to die from breast cancer in the same year. According to Cancer India, breast cancer is the most common cancer among women in India, making up 14% of all cancers in women. Therefore, the rising prevalence of breast and gastric cancer drives the demand for trastuzumab biosimilar, offering a cost-effective alternative to expensive medicines, consequently boosting the trastuzumab biosimilars market.

What Are The Key Segment Divisions In The Trastuzumab Biosimilars Market Segment Structure?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

What Trends Are Affecting The Growth Of The Trastuzumab Biosimilars Market?

Key industry participants are consistently prioritizing the introduction of novel offerings in previously unexplored geographical areas, thereby influencing the landscape of the trastuzumab biosimilars market. Entities engaged in the trastuzumab biosimilars market are undertaking diverse strategic measures, including the creation of new products, collaborations, and an expansion of their regional presence and product range, all aimed at preserving their market competitiveness and more effectively addressing customer requirements. An example of this is Accord BioPharma Inc., a pharmaceutical firm based in the US, which revealed in April 2024 that the U.S. Food and Drug Administration (FDA) had granted approval for HERCESSI (trastuzumab-strf). This product is a biosimilar to Herceptin (trastuzumab), designated for the Treatment of Several Forms of HER2-Overexpressing Cancer. HERCESSI’s indications include the adjuvant therapy for HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. While HER2-positive cancers typically exhibit aggressive characteristics, they demonstrate good responsiveness to targeted therapeutic interventions. The mechanism of action for HERCESSI involves attaching to the HER2 receptor, which in turn hinders its function and consequently decelerates the proliferation of cancer cells.

Which Organizations Are Engaged In The Trastuzumab Biosimilars Market?

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

Get The Full Trastuzumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Region Is The Leading Market For The Trastuzumab Biosimilars Market?

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Trastuzumab Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Trastuzumab Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Trastuzumab Biosimilars Market At The End Of The 2026–2030 Forecast Period?

The trastuzumab biosimilars market size has experienced significant expansion recently. Its valuation is projected to increase from $6.9 billion in 2025 to reach $8.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 28.5%. This historical expansion can be linked to several factors including the elevated occurrence of HER2 positive breast cancer, the expiration of trastuzumab patent exclusivity, an increase in oncology drug expenses, established regulatory pathways for biosimilars, and the growing acceptance within hospital oncology departments.

The trastuzumab biosimilars market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $24.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 28.9%. This forecasted growth stems from several factors, including the rising incidence of cancer, the extension of indications to include gastric cancer, supportive reimbursement policies for biosimilars, enhanced trust among physicians, and increased initiatives aimed at curbing healthcare costs. Key developments anticipated during this period encompass the swift adoption of oncology biosimilars, enhanced availability of HER2 targeted treatments, intense price rivalry within breast cancer therapy, broader application in hospital oncology settings, and increasing willingness to switch to biosimilars.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

What Primary Drivers Are Shaping The Development Of The Trastuzumab Biosimilars Market?

The increasing occurrence of breast and gastric cancer has fueled the expansion of the trastuzumab biosimilars market. Trastuzumab biosimilar serves as a treatment for human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For instance, in September 2023, the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, reported that approximately 297,790 new cases of invasive breast cancer were anticipated to be diagnosed in women in 2023, with about 43,700 women expected to succumb to breast cancer in the same year. Additionally, Cancer India indicates that breast cancer is the most common cancer in women in India, constituting 14% of all female cancers. Consequently, the growing incidence of breast and gastric cancer boosts the demand for trastuzumab biosimilar, which offers a cost-effective alternative to expensive medicines, thereby propelling the trastuzumab biosimilars market.

What Segment Types Make Up The Trastuzumab Biosimilars Market?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Which Market Trends Are Creating New Opportunities In The Trastuzumab Biosimilars Market?

Leading industry participants are consistently focusing on introducing new products into unaddressed regions, a trend that is significantly shaping the market for trastuzumab biosimilars. Companies operating within the trastuzumab biosimilars market are undertaking various strategic endeavors, such as developing new products, forming partnerships, and expanding their geographical reach and product portfolios, all to maintain their competitive standing and better cater to customer requirements. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer. HERCESSI is prescribed for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. While generally aggressive, HER2-positive cancers typically respond effectively to targeted therapies. HERCESSI operates by binding to the HER2 receptor, thereby inhibiting its activity and slowing down the replication of cancer cells.

Who Are The Key Players Driving Competition In The Trastuzumab Biosimilars Market?

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

Read the full trastuzumab biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

How Does The Trastuzumab Biosimilars Market Perform Across Major Global Regions?

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Trastuzumab Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3400&type=smp

Browse Through More Reports Similar to the Global Trastuzumab Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the trastuzumab biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Trastuzumab Biosimilars Market in 2030?

The trastuzumab biosimilars market has experienced considerable expansion in recent years. It is anticipated to increase from $6.9 billion in 2025 to $8.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 28.5%. The historical development in this market can be linked to a high incidence of HER2 positive breast cancer, the expiration of trastuzumab patent exclusivity, escalating oncology drug costs, established regulatory pathways for biosimilars, and the integration of oncology practices in hospitals.

The trastuzumab biosimilars market is anticipated to experience substantial expansion over the coming years. Its valuation is projected to reach $24.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 28.9%. This projected growth during the forecast period stems from factors such as the rising incidence of cancer, the broadening of indications to include gastric cancer, supportive reimbursement policies for biosimilars, increasing trust among physicians, and intensified efforts to control healthcare costs. Key trends expected within this period encompass the swift adoption of oncology biosimilars, enhanced availability of HER2-targeted therapies, competitive pricing strategies in breast cancer management, wider implementation of oncology services in hospitals, and an increasing willingness to switch to biosimilars.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

What Drivers Are Influencing Production Trends In The Trastuzumab Biosimilars Market?

The expansion of the trastuzumab biosimilars market was supported by the rising occurrence of breast and gastric cancer. Trastuzumab biosimilar is utilized in addressing human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For instance, in September 2023, the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, estimated that around 297,790 new instances of invasive breast cancer would be identified in women in 2023, and approximately 43,700 women would perish from breast cancer in the same year. Furthermore, according to Cancer India, breast cancer stands as the most prevalent cancer among women in India, accounting for 14% of female cancer cases. Consequently, the increasing prevalence of breast and gastric cancer enhances the need for trastuzumab biosimilar, offering a more affordable alternative to expensive medicines, thereby stimulating the trastuzumab biosimilars market.

Which Segments Are Gaining Traction In The Trastuzumab Biosimilars Market?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

What Trends Are Reshaping The Dynamics Of The Trastuzumab Biosimilars Market?

Major players are continuously prioritizing the introduction of new products into untapped territories, which significantly shapes the trastuzumab biosimilars market. Companies operating within this market are undertaking various strategic initiatives such as developing new products, establishing partnerships, and broadening their geographical presence and product offerings. These actions aim to maintain their competitive standing and better address customer needs. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for the treatment of several forms of HER2-Overexpressing Cancer. HERCESSI is specifically indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers are typically aggressive but show effective responses to targeted therapies. HERCESSI functions by attaching to the HER2 receptor, thereby impeding its activity and subsequently slowing down the multiplication of cancer cells.

Who Are The Major Companies Operating In The Trastuzumab Biosimilars Market?

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Trastuzumab Biosimilars Market?

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Trastuzumab Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3400&type=smp

Browse Through More Reports Similar to the Global Trastuzumab Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Trastuzumab Biosimilars Market In 2029?

The size of the trastuzumab biosimilars market has expanded significantly in the past few years. The market was worth $4.27 billion in 2024 and is projected to rise to $5.43 billion in 2025, showing a compound annual growth rate (CAGR) of 27.1%. The notable increase during the historic period is a result of factors such as extensive market expansion and global penetration, the expiration of patents and market entry, the swift development of biosimilars, the validation of clinical efficacy, and competitive pricing strategies.

What Growth Rate Is Forecasted for the Trastuzumab Biosimilars Market by 2029?

The market size for trastuzumab biosimilar is anticipated to experience a substantial surge in the near future, expanding to $14.69 billion by 2029 with a compound annual growth rate (CAGR) of 28.3%. The escalation during the projected period can be credited to factors such as heightened market competition, the progression of the biosimilar pipeline, regulatory consent and standardizations, global market invasion, as well as the adoption and prescribing habits of physicians. The prediction period will see major trends such as enhanced accessibility, market segmentation tactics, educational drives, patient leaning towards biosimilars, and physician approval.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

Which Key Companies Are Shaping the Future of the Trastuzumab Biosimilars Market?

Major companies operating in the trastuzumab biosimilars market include Pfizer Inc., Merck & Co., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

Which Factors Are Driving Demand in the Trastuzumab Biosimilars Industry?

The growing incidence of breast and stomach cancer has played a significant role in promoting the trastuzumab biosimilars market. Trastuzumab biosimilar is applied in treating human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic stomach cancer. The American Cancer Society, a US-based health organization intent on eradicating cancer, stated in September 2023, that approximately 297,790 fresh instances of invasive breast cancer are projected to occur in women in 2023, and about 43,700 women are estimated to succumb to breast cancer in the same year. Cancer India reports that breast cancer is the most prevalent cancer in Indian women, representing 14% of cancers in women. Hence, the escalating rates of breast and stomach cancer compound the demand for trastuzumab biosimilar, which is a cost-effective alternative to pricier medicines, stimulating the growth of the trastuzumab biosimilars market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3400&type=smp

How Is the Trastuzumab Biosimilars Market Segmented by Several Divisions?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

What are the Emerging Market Trends Driving the Growth of the Trastuzumab Biosimilars Industry?

The trastuzumab biosimilars market is being shaped by key players who are constantly launching new products in untapped regions. These companies are executing various strategic maneuvers like developing new products, forming partnerships, and expanding their geographic and product portfolios to retain market competitiveness and cater to customer needs better. For instance, in April 2024, US-based pharmaceutical firm Accord BioPharma Inc. secured approval from the U.S. Food and Drug Administration (FDA) for its biosimilar to Herceptin, known as HERCESSI (trastuzumab-strf), designed for treating multiple forms of HER2-Overexpressing Cancer. HERCESSI is principally prescribed for adjunctive treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. Despite HER2-positive cancers being generally aggressive, they respond effectively to targeted treatments. By binding to the HER2 receptor, HERCESSI inhibits its activity, thereby slowing the cancer cell reproduction.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Regions Are Driving Growth in the Trastuzumab Biosimilars Market?

The countries covered in the trastuzumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3400

This Report Delivers Insight On:

1. How big is the trastuzumab biosimilars market, and how is it changing globally?

2. Who are the major companies in the trastuzumab biosimilars market, and how are they performing?

3. What are the key opportunities and risks in the trastuzumab biosimilars market right now?

4. Which products or customer segments are growing the most in the trastuzumab biosimilars market?

5. What factors are helping or slowing down the growth of the trastuzumab biosimilars market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the trastuzumab biosimilars industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Trastuzumab Biosimilars Market In 2029?

The size of the trastuzumab biosimilars market has witnessed a massive growth in the past few years. The market, which stood at $4.27 billion in 2024, is projected to reach $5.43 billion in 2025, registering a compound annual growth rate (CAGR) of 27.1%. The impressive growth during the historical phase can be credited to factors like broadening of the market reach globally, expiration of the patent and entry into the market, swift development of biosimilars, validation of clinical efficacy, and competitive pricing strategies.

The market size of trastuzumab biosimilars is projected to undergo significant expansion in the coming years. It is predicted to reach $14.69 billion in 2029, escalating at a compound annual growth rate (CAGR) of 28.3%. The rise during the forecast duration is ascribed to the intensifying market rivalry, development of the biosimilar pipeline, establishment of regulatory approvals and standardizations, penetration of the global market, and patterns of physician adoption and prescribing. The forecast period will observe notable trends like enhanced access to trastuzumab biosimilars, market segmentation plans, informational campaigns, patient favoritism for biosimilars, and physician approval.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Trastuzumab Biosimilars Market?

The trastuzumab biosimilars market saw an increase due to the escalating instances of breast and gastric cancer. Used for treating human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer, trastuzumab biosimilar has seen growing demand. The American Cancer Society, a US-based voluntary health organization focused on cancer eradication, reported in September 2023 that around 297,790 new cases of invasive breast cancer would be diagnosed in women in 2023, leading to approximately 43,700 deaths from breast cancer within the same year. On a similar note, Cancer India states that breast cancer is the predominant cancer in Indian women, composed of 14% of all cancer cases in women. Consequently, the climbing prevalence of breast and gastric cancer heightens the need for trastuzumab biosimilar, offering a less costly alternative to expensive medications, thus propelling the expansion of the trastuzumab biosimilars market.

Which Key Market Segments Comprise the Trastuzumab Biosimilars Market and Drive Its Revenue Growth?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3400&type=smp

Which Areas Are Leading Regions in the Trastuzumab Biosimilars Market Expansion Across the Globe?

The countries covered in the trastuzumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Are the Key Market Trends in the Trastuzumab Biosimilars Market Over the Coming Years?

Leading entities are consistently emphasizing on introducing new products in unexplored areas, thereby shaping the trastuzumab biosimilars market. Companies functioning in this market are taking several strategic steps such as developing new products, entering partnerships, and expanding their geographical presence and product portfolio to hold their competitive edge and cater more effectively to consumer requirements. For example, Accord BioPharma Inc., a pharmaceutical company based in the US, declared in April 2024 that it has received approval from the U.S. Food and Drug Administration (FDA) for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab) used for treating various forms of HER2-Overexpressing Cancer. HERCESSI is recommended for the additional treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. Even though HER2-positive cancers are typically aggressive, they exhibit an effective response to targeted therapies. HERCESSI operates by binding to the HER2 receptor, suppressing its activity, and as a result, decelerating the reproduction of cancer cells.

View the full report here:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

How Is the Trastuzumab Biosimilars Market Conceptually Defined?

Trastuzumab biosimilar refers to a HER2-targeted therapy drug that is designed to treat early and metastatic HER2-positive breast cancers. Trastuzumab biosimilar is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2)/neu receptor and renders it inactive

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3400

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Trastuzumab Biosimilars Market?

The increasing prevalence of breast and gastric cancer is driving the demand for trastuzumab biosimilars. Trastuzumab biosimilars are used to treat HER2 overexpressing breast cancer and metastatic gastric cancer. In September 2023, the American Cancer Society reported that nearly 298,000 new breast cancer cases would be diagnosed in the US, further increasing the demand for cost-effective biosimilars, thus boosting the trastuzumab biosimilars market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

#What Growth Opportunities Will Drive the Trastuzumab Biosimilars Market’s CAGR Through 2034?

The trastuzumab biosimilars market size has grown exponentially in recent years. It will grow from $4.27 billion in 2024 to $5.43 billion in 2025 at a compound annual growth rate (CAGR) of 27.1%. The growth is driven by market expansion, patent expiry, rapid biosimilar development, clinical efficacy validation, and competitive pricing strategies.

The trastuzumab biosimilars market is expected to see exponential growth, reaching $14.69 billion by 2029 at a CAGR of 28.3%. Growth will be driven by intensified market competition, the development of biosimilar pipelines, regulatory approvals and standardizations, global market penetration, and changes in physician adoption and prescribing patterns. Key trends include improved access to biosimilars, market segmentation strategies, educational campaigns, growing patient preference for biosimilars, and physician acceptance.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3400

What New Market Trends Are Reshaping theTrastuzumab Biosimilars Market and Its Opportunities?

In the trastuzumab biosimilars market, companies are focused on new product development and expanding into untapped regions. For example, in April 2024, Accord BioPharma Inc. received FDA approval for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin, which targets HER2-positive cancers. This treatment, designed for aggressive cancers, is a targeted therapy that inhibits the HER2 receptor to slow down cancer cell replication.

Who Are the Top Companies Driving Innovation and Growth in theTrastuzumab Biosimilars Market?

Major companies operating in the trastuzumab biosimilars market include Pfizer Inc., Merck & Co., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Key Market Segments Comprise the Trastuzumab Biosimilars Market and Drive Its Revenue Growth?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=3400&type=smp

Which Regions Are Emerging as Leaders in the Trastuzumab Biosimilars Market?

The countries covered in the trastuzumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

Browse Through More Reports Similar to the Global Trastuzumab Biosimilars Market 2025, By The Business Research Company:

Oral Biologics & Biosimilars Global Market Opportunities And Strategies To 2030

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: